prostate-report.org

Following Successful Completion of Final Clinical Trials a New Prostate Cancer Test is Ready for Commercialization

Health Discovery Corporation announced that HDC’s new gene-based molecular diagnostic test for prostate cancer has now successfully completed it’s Phase III double-blind clinical trial and is now ready for commercialization to be used by physicians on their patients at risk of having prostate cancer. The new prostate cancer test will be performed at Clarient’s Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty on each test performed.

The excellent results seen in Phase I, Phase II, and Phase III double-blinded clinical trials validate the scientific accuracy and robustness of the HDC gene-based molecular diagnostic test for prostate cancer. Physicians that are diagnosing and treating prostate cancer patients will be greatly assisted by the additional information that this new prostate cancer test will add to their decision making process.

According to a head of Clarient they are very impressed with the results from these validation studies, and they applaud the development teams from both Clarient and HDC for their diligent efforts in bringing this new test through the validation phase significantly ahead of schedule. The early results from these studies confirm the belief that this powerful genomics-based test may provide physicians with useful information to ensure that men with prostate cancer get a more accurate diagnosis sooner and minimize the need for unnecessary biopsies.